№ 5 / 2017 / 26-32

GOLIMUMAB, TNF-α INHIBITOR, IN INTEGRATED METHODS OF THE TREATMENT OF AVASCULAR NECROSIS OF THE FEMORAL HEAD IN PATIENTS WITH PSORIATIC ARTHRITIS

Author: Shusharin A.G.¹, Polovinka M.P.², Prokhorenko V.M.³

Abstract

Aim of the study – to investigate the efficacy and safety of golimumab in patients with psoriasis and psoriatic arthritis in the active phase, to which aseptic necrosis of the femoral head was diagnosed by MRI and who held courses with intra-articular injections of perftoran and dimexide. Material and methods. In a pilot clinical study, adult patients (n = 14) aged 32–49 (9 men and 5 women) with PsA, active Ps and early stages of aseptic necrosis of the femoral head took part. Ps in all patients has been diagnosed since childhood; PsA is diagnosed on average 8.2 years after the onset of Ps. All patients were given methotrexate as a baseline before enrollment. Evaluation of the effectiveness of treatment for PsA was performed in accordance with the criteria of the American College of Rheumatology (ACR), assessment of the prevalence of Ps in patients was carried out in accordance with the PASI75. Results and discussion. Evaluation of the results of golimumab therapy was performed at 12, 24 and 48 weeks. At week 12, ACR20 was achieved in 64 % of patients, ACR50 and ACR70 in 29 and 7 % of patients, respectively. By week 24 (after 6 injections), the response according to the criteria of the American College of Rheumatology (ACR20/50/70) was 86, 71 and 57 %, respectively. By the end of the 48th week the positive dynamics persisted: ACR 20/50/70 – 93, 86 and 79 %, respectively. The number of patients reached by the 12th week of PASI75 was 14 %. In 7 patients (50 %), aseptic necrosis in the stage of recovery, and a decrease in the degree of ANFH were observed by week 48 with MRI. Conclusion. Our experience has demonstrated the clinical effectiveness of golimumab therapy in all patients. In the majority (85.7 %) patients with psoriasis and psoriatic arthritis, a significant positive dynamics was achieved already 24 weeks after the start of therapy. It has been shown that treatment with golimumab is compatible with the courses of intraarticular injections of a drug mixture of perftoran and dimexide in the hip joint in patients with early stages of aseptic necrosis; positive dynamics is expressed in the inhibition of destructive changes in bone tissue and removal of edema of the bone marrow.

Key words

psoriatic arthritis, psoriasis, golimumab, aseptic necrosis of the femoral head, intra-articular injections under ultrasound contro, perftoran, dimexide

References

Antoni C., Krueger G.G., de Vlam K. et al. Infliximab improves signs and symptoms of psoriatic arthritis: results of the IMPACT 2 trial // Ann. Rheum. Dis. 2005. 64. (8). 1150-1157.

ARCO (Association Research Circulation Osseous): committee on terminology and classification // ARCO News. 1992. 4. 41-46.

Badokin V.V. Perspectives for the use of TNF-α inhibitors in psoriasis and psoriatic arthritis // Klinicheskaya farmakologiya i terapiya = Clinical pharmacology and therapy. 2005. 14. (1). 76-79. [In Russian].

Badokin V.V. Psoriatic arthritis (clinic, diagnosis, treatment) // Nauchno-prakticheskaya revmatologiya = Rheumatology Science and Practice. 2006. 44. (2s). 65-77. [In Russian].

Badokin V.V. The tumor necrosis factor-alpha is the main target of pathogenetic therapy of psoriasis and psoriatic arthritis // Dermatologiya = Dermatology. 2006. (1). 27-31. [In Russian].

Bunchuk N.V., Badokin V.V., Korotaeva T.V. Psoriatic arthritis // Rheumatology: national leadership. Moscow: GEOTAR-MEDIA, 2008. 355-366. [In Russian].

Christophers E. Psoriasis - epidemiology and clinical spectrum // Clin. Exp. Dermatol. 2001. 26. (4). 314-320.

Fiocco U., Sfriso P., Oliviero F. et al. Blockade of intra-articular TNF in peripheral spondyloarthritis: its relevance to clinical scores, quantitative imaging and synovial fluid and synovial tissue biomarkers // Joint Bone Spine. 2013. 80. 165–170.

Fitzgerald O., Dougados M. Psoriatic arthritis: one or more diseases? // Best Pract. Res. Clin. Rheumatol. 2006. 20. (3). 435-450.

Gladman D.D., Antoni C., Mease P. et al. Psoriatic arthritis: epidemiology, clinical features, course, and outcome // Ann. Rheum. Dis. 2005. 64. (Suppl. 2). ii14-ii17.

Haroon M., Gallagher P., Heffernan E. et al. High prevalence of metabolic syndrome and of insulin resistance in psoriatic arthritis is associated with the severity of underlying disease // J Rheumatol. 2014. 41. (7). 1357-1365.

Helmick C.G., Lee-Han H., Hirsch S.C. et al. Prevalence of psoriasis among adults in the U.S.: 2003–2006 and 2009–2010 National Health and Nutrition Examination Surveys // Am. J. Prev. Med. 2014. 47. (1). 37–45.

Hussar D.A. New drugs: Golimumab, besifloxacin hydrochloride, and artemether / lumefantrine // J. Am. Pharm. Ass. 2009. 49. (4). 570-573.

Huynh D., Kavanaugh A. Psoriatic arthritis: current therapy and future directions // Expert Opin Pharmacother. 2013. 14. 1755–1764.

Ibrahim G., Waxman R., Helliwell P.S. The prevalence of psoriatic arthritis in people with psoriasis // Arthritis Rheum. 2009. 61. (10). 1373-1378.

Jamnitski A., Symmons D., Peters M.J. et al. Cardiovascular comorbidities in patients with psoriatic arthritis: a systematic review // Ann. Rheum. Dis. 2013. 72. (2). 211-216.

Kavanaugh A., Antoni C.E. Gladman D. et al. The infliximab multinational psoriatic arthritis controlled trial (IMPACT): results of radiographic analyses after 1 year // 006. 65. (8). 1038-1043.

Kane D., Stafford L., Bresnihan B. et al. A prospective, clinical and radiological study of early psoriatic arthritis: an early synovitis clinic experience // Rheumatology. 2003. 42. (12). 1460-1468.

Kavanaugh A., McInnes I., Mease P. et al. Golimumab, a new human tumor necrosis factor alpha antibody, administered every four weeks as a subcutaneous injection in psoriatic arthritis twenty-four-week efficacy and safety results of a randomized, placebo-controlled study // Arthritis Rheum. 2009. 60. (4). 976-986.

Kavanaugh A., McInnes I.B., Mease P. et al. Clinical efficacy, radiographic and safety findings through 5 years of subcutaneous golimumab treatment in patients with active psoriatic arthritis: results from a long-term extension of a randomised, placebo-controlled trial (the GO-REVEAL study) // Ann. Rheum. Dis. 2014. 73. (9). 1689-1694.

Korotaeva N.V. Results of an evaluation of the efficacy and safety of a new inhibitor of tumor necrosis factor α - golimumab in the treatment of psoriatic arthritis // Nauchno-prakticheskaya revmatologiya = Rheumatology Science and Practice. 2012. (3. Suppl. 3). 17-22. [In Russian].

Lebwohl M. Psoriasis // Lancet. 2003. 361. (9364). 1197-1204.

Lowes M.A., Bowcock A.M., Krueger J.G. Pathogenesis and therapy of psoriasis // Nature. 2007. 445. (7130). 866-873.

Martínez-Ferrer M.A., Peris P., Guañabens N. Osteonecrosis. What is new? // Reumatol. Clin. 2007. 3. (2). 78-84.

Mcdonough E., Ayearst R., Eder L. et al. Depression and anxiety in psoriatic disease: prevalence and associated factors // J. Rheumatol. 2014. 41. (5). 887-896.

McLaughlin M., Ostör A. Early treatment of psoriatic arthritis improves prognosis // Practitioner. 2014. 258. (1777). 21-24.

Mease P.J., Gladman D.D., Ritchlin C.T. et al. Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis - Results of a double-blind, randomized, placebo-controlled trial // Arthritis Rheum. 2005. 52. (10). 3279–3289.

Mease P.J., Kivitz A.J., Burch F.X. et al. Etanercept treatment of psoriatic arthritis - Safety, efficacy, and effect on disease progression // Arthritis Rheum. 2004. 50. (7). 2264-2272.

Menter A., Gottlieb A., Feldman S.R. et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics // J. Am. Acad. Dermatol. 2008. 58. (5). 826-850.

Meyer N., Paul C., Feneron D. et al. Psoriasis: an epidemiological evaluation of disease burden in 590 patients // J. Eur. Acad. Dermatol. Venereol. 2010. 24. (9). 1075-1082.

Minnock P., Kirwan J., Veale D. et al. Fatigue is an independent outcome measure and is sensitive to change in patients with psoriatic arthritis // Clin. Exp. Rheumatol. 2010. 28. (3). 401-404.

Myers W., Opeola M., Gottlieb A.B. Common clinical features and disease mechanisms of psoriasis and psoriatic arthritis // Curr. Rheumatol. Rep. 2004. 6. (4). 306-313.

Nograles K.E., Davidovici B., Krueger J.G. New insights in the immunologic basis of psoriasis // Semin. Cutan. Med. Surg. 2010. 29. (1). 3–9.

Ogdie A., Schwartzman S., Eder L. et al. Comprehensive treatment of psoriatic arthritis: managing comorbidities and extraarticular manifestations // J. Rheumatol. 2014. 41. (11). 2315-2322.

Parisi R., Symmons D.P., Griffiths C.E. et al. Global epidemiology of psoriasis: a systematic review of incidence and prevalence // J. Invest. Dermatol. 2013. 133. (2). 377-385.

Patent 2487736 RF. A method for treating of aseptic necrosis of the femoral head / Shusharin A.G., Polovinka M.P., Morozov V.V.; published. 20.07.2013. [In Russian].

Prinz J. The role of T cells in psoriasis // J. Eur. Acad. Dermatol. Venereol. 2003. 17. (3). 257-270.

Punzi L., Podswiadek M., Sfriso P. et al. Pathogenetic and clinical rationale for TNF-blocking therapy in psoriatic arthritis // Autoimmun. Rev. 2007. 6. 524–528.

Rapp S.R., Feldman S.R., Exum M.L. et al. Psoriasis causes as much disability as other major medical diseases // J. Am. Acad. Dermatol. 1999. 41. (3, Pt. 1). 401-407.

Raychaudhuri S.P., Wilken R., Sukhov A.C. et al. Management of psoriatic arthritis: Early diagnosis, monitoring of disease severity and cutting edge therapies // J. Autoimmun. 2017. 76. 21-37.

Scarpa R., Atteno M., Lubrano E. et al. The effectiveness and safety of TNF-alpha blockers in the treatment of early psoriatic arthritis: an Italian multicentre longitudinal observational pilot study // Clin. Rheumatol. 2011. 30. 1063–1067.

Schön M.P., Boehncke W.H. Psoriasis // N. Engl. J. Med. 2005. 352. (18). 1899–1912.

Shusharin A.G., Polovinka M.P., Prokhorenko V.M. Estimation of efficiency of conservative treatment aseptic necrosis of the femoral head // Sibirskiy nauchnyy medtsinskiy zhurnal = Siberian Scientific Medical Journal. 2015. 35. (3). 53–58. [In Russian].

Steshenko I.G., Kalyagin A.N. Possibilities of therapy of advanced psoriasis of the skin and psoriatic arthritis with the use of TNF-α blocker (golimumab) // Sovremennye problemy revmatologii = Modern problems of rheumatology. 2014. 6. (6). 57-61. [In Russian].

Sukhov A., Adamopoulos I.E., Maverakis E. Interactions of the immune system with skin and bone tissue in psoriatic arthritis: a comprehensive review // Clin. Rev. Allergy Immunol. 2016. 51. (1). 87-99.

About Authors (Correspondence):

Polovinka M.P. – candidate of chemical sciences, associate professor of the department of organic chemistry, e-mail: marinapolovinka@yandex.ru

Full Text

snmzh_5-2017_shusharin_i_dr.pdf

Received: 30/10/2017

Accepted: 30/10/2017